Director & 10% Owner OrbiMed Buys $12.5M in Prelude Therapeutics Stock
PRLD has more than doubled off its 52-week low of $0.73 on elevated volume (2.2× avg).
Summary
A Director and 10% owner, representing OrbiMed, purchased $12.5 million in Prelude Therapeutics common stock through an underwritten public offering, signaling strong institutional backing.
Key Events · Ownership and Investor Activity · PRLD
-
Significant Institutional Investment
David P. Bonita, a Director and 10% owner representing OrbiMed, acquired $12,499,999 worth of common stock.
-
Participation in Public Offering
The purchase of 2,815,315 shares at $4.44 per share was made on April 21, 2026, as part of an underwritten public offering.
-
Strong Vote of Confidence
This substantial investment follows Prelude Therapeutics' recent $90 million capital raise and another major institutional purchase, indicating robust institutional support and strengthening the company's financial position.
Analysis · PRLD · Life Sciences
This significant open market purchase by David P. Bonita, a Director and representative of OrbiMed, demonstrates strong institutional confidence in Prelude Therapeutics. The $12.5 million investment, made as part of an underwritten public offering at $4.44 per share, follows closely on the heels of the company's recent $90 million capital raise and another major institutional investment from Baker Bros. Advisors. This cluster of institutional buying provides a substantial vote of confidence and strengthens the company's financial position, extending its cash runway.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.8% of the 571 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRLD was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.2M. The 52-week trading range was $0.73 to $5.54. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.